Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 11,211 $ 9,589
Marketable securities, current 26,755 39,091
Collaboration receivable 777 1,891
Prepaid expenses and other current assets 1,880 2,599
Total current assets 40,623 53,170
Property and equipment, net 261 333
Other assets 166 166
Total assets 41,050 53,669
Current liabilities:    
Accounts payable 1,563 725
Accrued clinical and development expenses 3,325 6,834
Accrued liabilities 687 3,269
Total current liabilities 5,575 10,828
Warrant liability 1,494 1,864
Deferred rent 109 131
Total liabilities $ 7,178 $ 12,823
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,511,425 shares at March 31, 2016 and 71,462,059 shares at December 31, 2015 $ 72 $ 71
Additional paid-in capital 371,091 370,236
Accumulated other comprehensive loss 1 (21)
Accumulated deficit (337,292) (329,440)
Total stockholders’ equity 33,872 40,846
Total liabilities and stockholders’ equity $ 41,050 $ 53,669